Efficacy of abobotulinumtoxinA versus onabotulinumtoxinA for the treatment of refractory neurogenic detrusor overactivity: a systematic review and indirect treatment comparison.

Francisco CruzNatalya DanchenkoKyle FahrbachAndreas FreitagJialu TarpeyJohn Whalen

Published in: Journal of medical economics (2023)

There may be potential advantages of aboBoNT-A over onaBoNT-A, in terms of UI reduction, in patients with refractory NDO. More confirmatory studies are needed owing to sparsity of current evidence.

Keyphrases

combination therapy
risk assessment
climate change
botulinum toxin
case control